The Honorable Anna G. Eshoo  
U.S. House of Representatives  
272 Cannon House Office Building  
Washington, DC 20515

The Honorable Brett Guthrie  
U.S. House of Representatives  
2434 Rayburn House Office Building  
Washington, DC 20515

The Honorable Frank Pallone, Jr  
U.S. House of Representatives  
2107 Rayburn House Office Building  
Washington, DC 20515

The Honorable Cathy McMorris Rodgers  
U.S. House of Representatives  
1035 Longworth House Office Building  
Washington, DC 20515

September 9, 2021

Dear Chairs and Ranking Members of the Energy and Commerce, Full Committee and Health Subcommittee:

The undersigned organizations, representing clinicians, scientists, patients, public health, animal agriculture and the pharmaceutical and diagnostics industries appreciate your leadership on public policy priorities affecting the nation’s health, and we urge you to convene a hearing on the worsening crisis of antimicrobial resistance (AMR); potential economic solutions to address the current market challenges that impact antimicrobial drug development; and policies to strengthen infection prevention, antimicrobial stewardship, surveillance and research.

Antibiotic resistance is one of the greatest public health threats of our time. Drug-resistant infections sicken at least 2.8 million people and kill at least 35,000 people in the United States each year. Antibiotic resistance accounts for direct health care costs of at least $20 billion. Globally, over 700,000 people die each year, imposing economic and health systems costs as high as $1.2 trillion. If we do not act now, antibiotic resistant infections will be the leading cause of death by 2050 and could cost the world $100 trillion.

Strengthening our ability to combat AMR is also central to our nation’s public health and pandemic preparedness. Secondary resistant infections have challenged our COVID-19 response and increased mortality among patients commonly affected by secondary bacterial infections. High levels of antibiotic overuse among COVID-19 patients, particularly earlier in the pandemic, may have driven the development of new resistance threats which we have not yet identified and for which we are unprepared. Innovation to advance the rapid development of new antimicrobials is critical to address the AMR threat and secure the nation’s biopreparedness against an uncertain future, and solutions must be included in any efforts to strengthen our public health infrastructure and preparedness efforts.

Unfortunately, the pipeline of new and innovative antimicrobials in development worldwide is woefully insufficient to meet patient needs. Small companies that are responsible for nearly all current antibiotic innovation are struggling to sustain operations. Factors unique to antibiotics,
including the need to use these drugs sparingly, make it challenging for companies to earn a reasonable return on investment. As a result, many companies have either closed their antibiotics research programs voluntarily or gone bankrupt. New incentives, particularly those that address post-market challenges through stable, upfront revenue commitments, are urgently needed to spur antibiotic research and development (R&D), revitalize the pipeline, and ultimately curb the spread of AMR.

As you may know, in October 2020 the Department of Health and Human Services (HHS) released the new National Action Plan for Combating Antibiotic Resistant Bacteria (CARB) 2021-2025. This plan contains many important goals and objectives, but notably lacks recommendations surrounding the type of novel financing mechanism necessary to sustain antibiotic R&D. The plan also aims to build on progress to strengthen antibiotic stewardship, infection prevention, surveillance and research, as key gaps persist in all these areas. In particular, antibiotic stewardship programs, now required in hospitals and long-term care facilities, remain sorely under resourced and have been forced to pivot activities during the pandemic to lead administration of COVID-19 therapies. A thorough review of our national progress in combating AMR and an assessment of emerging and persistent needs will be important to ensure accountability and make continued meaningful headway.

Your committee is uniquely well positioned to deepen public awareness and dialogue around the crisis of antimicrobial resistance and to advance constructive solutions, including the Doyle-Ferguson-Bennet-Young PASTEUR Act (H.R. 3932 / S. 2076), and we strongly urge you to consider holding a hearing on these issues in the fall. We thank you for your attention and look forward to working with you.

Sincerely,

Accelerate Diagnostics, Inc.
Alliance for Aging Research
American Academy of Allergy, Asthma & Immunology
American Association of Bovine Practitioners
American Association of Small Ruminant Practitioners
American Public Health Association
American Society for Microbiology
American Society of Plastic Surgeons
American Society of Tropical Medicine & Hygiene
Amputee Coalition
Antimicrobial Innovation Alliance
Association for Professionals in Infection Control and Epidemiology
Association of Community Cancer Centers (ACCC)
Association of State and Territorial Health Officials
Biocom
bioMerieux, Inc.
BioNJ
Biotechnology Innovation Organization (BIO)
California Life Sciences
Center for Disease Dynamics, Economics & Policy
Peter W. Choo, MD, DrPH, MBA affiliated with Mass Medical Angels
Clarametyx Biosciences, Inc.
Coalition for Improving Sepsis and Antibiotic Practices (CISAP)
Cystic Fibrosis Foundation
The Emory Antibiotic Resistance Center
FasterCures, a center of the Milken Institute
Genentech, Inc., a member of the Roche Group
The Gerontological Society of America
Global Health Technologies Coalition (GHTC)
HealthyWomen
HIV Medicine Association
Infectious Diseases Society of America (IDSA)
The Joint Commission
Life Sciences Pennsylvania
Lymphoma Research Foundation
Making-a-Difference in Infectious Diseases
Merck & Co.
National Association of Pediatric Nurse Practitioners
NTM Info & Research, Inc.
Novo Holdings
ONCORD, Inc.
Professor Kevin Outterson, Boston University
The Partnership to Fight Infectious Diseases
The Peggy Lillis Foundation
The Pew Charitable Trusts
Qpex Biopharma, Inc.
Research!America
Sepsis Alliance
The Society of Infectious Diseases Pharmacists (SIDP)
Spero Therapeutics, Inc.
The Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance at Tufts (Levy CIMAR)
TB Alliance
Trust For America’s Health
Venatorx Pharmaceuticals, Inc.
Vizient, Inc.